Blood thinner to prevent heart clots after a heart attack
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests a blood thinner, rivaroxaban, to see if it can prevent blood clots from forming in the heart after a specific type of heart attack (STEMI) that affects the front part of the heart.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had chest pain for at least 30 minutes with heart attack signs on an EKG.
- You are willing to take a study medication daily.
- You have not had serious bleeding in the last 6 months.
- You are not already taking a blood thinner for other reasons.
- You do not have severe liver, kidney, or lung problems.
- You are not taking certain drugs that could interact with the study medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares different blood-thinner (“antithrombotic”) strategies in people with atrial fibrillation or flutter who recently had a stent placed (PCI). It aims to find a plan that lowers clot risk while keeping bleeding risk as low as possible.
This trial tests two different blood-thinner strategies for people who have had a recent heart attack and also have a widened artery (ectasia) in the heart. The goal is to find the safest and most effective way to prevent another heart attack or clot.
This trial tests whether a blood thinner called rivaroxaban helps improve slow blood flow in heart arteries after a stent placement for a heart attack. It may help reduce complications by keeping the arteries open better.
This trial tests how to use a blood thinner in people after a recent heart attack who have a clot in the left heart chamber confirmed by heart MRI. It may help lower the risk of the clot causing serious complications, but it also requires careful bleeding-safety screening.
This trial is testing whether a newer type of blood thinner (called a NOAC) can be used safely right after a heart attack or related event, in addition to the standard two antiplatelet medicines. It focuses on patients who have higher risk signs, like elevated D-dimer levels or a higher PARIS risk score, to see if this approach is safe and effective at preventing future heart problems.
This trial studies whether a specific blood thinner can better treat a left-side heart clot found soon after a heart attack. It may help prevent the clot from getting worse or causing complications.
Hear when a new STEMI - ST Elevation Myocardial Infarction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.